$1.82
▲ +0.6% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
ProQR Registers Shares for Resale by Investor
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating
ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint
Overview
52-week range
$1.33
$3.10
28% of range
Avg surprise (last 3)
-32.4%
Avg reaction (last 2)
-0.9%
0% positive
Latest IV / EM
46%
EM ±10.6% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.15 | $-0.15 | 0.0% | -36.4% | -0.6% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-0.14 | $-0.08 | -75.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.11 | $-0.09 | -22.2% | — | -1.3% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.14 | -$0.14 | 0.0% |